ArticleCureus2025
Epidemiology and Antifungal Susceptibility of Candida Bloodstream Isolates From a Tertiary Care Center in Central India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFungal bloodstream infections (BSIs), particularly candidemia, are recognized as major contributors to hospital-acquired infections and mortality. Early species and antifungal drug resistance pattern identification are crucial for timely intervention and improved outcomes. Consequently, this study aimed to examine the distribution of
methodsThis retrospective observational study was conducted between January and December 2024.
resultsCandidemia was detected in 118 (0.73%) of total blood culture samples (
conclusionsThe increasing prevalence of non-albicans Candida (NAC) species and the rising resistance to commonly used antifungals, particularly azoles, underscore the importance of timely diagnosis, species-level identification, antifungal drug resistance testing, and targeted antifungal therapy for candidemia. Higher antifungal drug resistance to posaconazole and fluconazole across several Candida isolates highlights the importance of routine antifungal drug resistance testing for Candida isolates in BSIs. Echinocandins are generally effective against most
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.